List view / Grid view
16 April 2015 | By Victoria White
Active Biotech and Ipsen discontinue the development of prostate cancer drug tasquinimod and have released top line results for the 10TASQ10 study...
16 April 2015 | By Victoria White
Actelion has initiated Phase III development with ponesimod, its lead compound, in patients suffering from relapsing multiple sclerosis (MS)...
16 April 2015 | By Victoria White
The melanoma treatment market will increase from $1.34 billion in 2013 to $5.64 billion by 2023, representing a robust CAGR of 15.5%, reports GlobalData...
16 April 2015 | By Victoria White
Cellmid Limited has reported strong positive results in its independently conducted, blinded and placebo controlled human clinical study of évolis ONE...
15 April 2015 | By Victoria White
Soligenix and the FDA have reached an agreement on the design of a pivotal Phase 3 trial evaluating SGX203 in the treatment of paediatric Crohn’s disease...
15 April 2015 | By Victoria White
The Phase 2 clinical trial of Imprime PGG and bevacizumab achieved meaningful reductions in tumour burden in patients with non-small cell lung cancer...
15 April 2015 | By Victoria White
The global treatment market for Duchenne Muscular Dystrophy will expand in value at a CAGR of 160.5% to $990 million by 2019, says GlobalData...
15 April 2015 | By Victoria White
The Phase 3 PALOMA-3 trial for IBRANCE has been stopped early due to efficacy seen in women with HR+, HER2- metastatic breast cancer...
15 April 2015 | By Daiichi Sankyo
Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation...
15 April 2015 | By Victoria White
WHO has issued a public statement calling for the disclosure of results from clinical trials for medical products, whatever the result...
15 April 2015 | By Victoria White
The U.S. Food and Drug Administration (FDA) has agreed to the proposed Phase 3 clinical development programme for Motif’s lead product candidate, iclaprim...
15 April 2015 | By Victoria White
The European Regulatory Authority has approved Omeros’ OMS721 for compassionate use in two patients with with thrombotic microangiopathy...
14 April 2015 | By Victoria White
Incyte's base for European clinical development operations is to be based in Geneva, Switzerland. Incyte is to occupy a 9,000 sq. ft. facility by mid-2015...
14 April 2015 | By Victoria White
Merck is introducing diabetes management training for more than 5,000 Maharashtra University students as part of the Merck Capacity Advancement Program...
14 April 2015 | By Victoria White
The Changing Diabetes in Children programme, a scheme that has provided free insulin to 13,000 children since 2009, has been extended by three years.
